# Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

> **NCT06547944** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 30 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Newly Diagnosed

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Lenalidomide
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT06547944
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06547944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06547944, "Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06547944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*